Roche (OTCMKTS:RHHBY) Coverage Initiated by Analysts at Morgan Stanley

Morgan Stanley initiated coverage on shares of Roche (OTCMKTS:RHHBY) in a research note published on Wednesday, Marketbeat.com reports. The firm issued an equal weight rating on the stock.

Separately, Sanford C. Bernstein upgraded shares of Roche to a “strong-buy” rating in a research note on Thursday, January 30th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold”.

Roche Price Performance

OTCMKTS RHHBY opened at $40.23 on Wednesday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.97 and a current ratio of 1.26. Roche has a one year low of $29.20 and a one year high of $42.43. The firm’s fifty day moving average is $36.77 and its two-hundred day moving average is $38.30.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in RHHBY. AlphaMark Advisors LLC acquired a new position in shares of Roche during the third quarter worth about $149,000. Kornitzer Capital Management Inc. KS increased its stake in shares of Roche by 1.3% during the third quarter. Kornitzer Capital Management Inc. KS now owns 136,923 shares of the company’s stock worth $5,490,000 after acquiring an additional 1,798 shares during the period. Verity Asset Management Inc. acquired a new position in shares of Roche during the third quarter worth about $253,000. Canopy Partners LLC increased its stake in shares of Roche by 4.6% during the third quarter. Canopy Partners LLC now owns 7,772 shares of the company’s stock worth $310,000 after acquiring an additional 344 shares during the period. Finally, Brooklyn Investment Group acquired a new position in shares of Roche during the third quarter worth about $40,000.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.